News
More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
14h
Medpage Today on MSNGLP-1 Drugs May Hold Benefit in Painful Skin Disease
In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...
Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed ...
Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...
Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...
22h
HealthDay on MSNGLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.
GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity. However, recent studies suggest they can lower blood pressure, reduce inflammation and improve lipid disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results